adjuvant therapies - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.88 [0.64, 1.20]< 10%1 study (1/-)79.5 %some concernnot evaluable moderatecrucial-
clinical improvement (28-day) 1.27 [1.03, 1.57]> 10%1 study (1/-)98.6 %some concernnot evaluable moderateimportant-
death or ventilation 0.82 [0.63, 1.07]< 10%1 study (1/-)92.9 %some concernnot evaluable moderateimportant-

safety endpoints 00

Major bleeding 1.80 [0.88, 3.67]< 10%1 study (1/-)5.3 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.